Alebund Pharmaceuticals receives FDA clearance for kidney disease trial
Alebund Pharmaceuticals received U S Food and Drug Administration investigational new drug clearance to commence clinical trials for AP308 targeting treatment of IgA nephropathy kidney disease
We haven't written up this one. Vietnam Investment Review has the full story — the link below goes straight to it.